Skip to main content

MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better?

To the Editor,

Aerosol bronchodilator therapy via nebulization using a nebulizer or metered dose inhaler (MDI) with a spacer device or dry powder inhaler is the mainstay in the treatment of COPD. We, herein, discuss two such cases with corresponding concerns related to various modes of bronchodilation in moderate to severe COVID-19 patients with COPD.

Two COVID-19 patients (60 years/M and 55 years/M) with COPD presented with worsening fever, cough, and shortness of breath for around 10 days. Chest radiographs revealed mid and lower lung zone involvement in both. Both received tazobactam-piperacillin for a period of 10 days and 12 days respectively, along with teicoplanin, ivermectin, hydroxychloroquine, enoxaparin, dexamethasone, salmeterol MDI, and multivitamin, and received oxygen via high FiO2 non-rebreathing mask and maintained 92–94% oxygen saturation and 24–32 breaths/min (FiO2 delivered was 0.8–1). We witnessed their inability to achieve an optimal peak inspiration with MDI and thus increased the dose to @ 4–6 puffs. Following no improvement, nebulization was started. Jet nebulizer was used, and levosalbutamol was used. The device contained mouthpiece with expiratory valve, but there was no filter available on the outlet end. Nevertheless, extreme caution was taken in ensuring safety of the health care workers, as all donned PPE. With improvement in peak inspiratory flow rate (more than 60 L/min), the MDIs were reinstituted. The pulmonary symptoms improved and both the patients were discharged subsequently. The total duration of stay in hospital was 17 days and 22 days respectively. Both patients got intensive nebulization therapy QID for a period of 4–5 days. A written informed consent for publication was obtained from both the patients.

Discussion

Bronchodilator delivery by MDI or wet nebulizer has been found to be equivalent in the acute treatment of adults with airflow obstruction (Turner et al., 1997). A Cochrane review (van Geffen et al., 2016) observed no significant difference in FEV1 at 1 h after dosing between nebulization and MDI; however, an improved FEV1 trend was observed with nebulization (van Geffen et al., 2016).

In critically ill patients, nebulization is preferred over MDI or DPI (dry powder inhaler) as the latter needs an optimal peak inspiratory flow rate (approx. 60 L/min) which is often compromised in critical illness. During COVID pandemic, bronchodilation via nebulization has got serious concern, i.e., the nebulizers produce small- and medium-size aerosol range and can disperse viral particles in exhaled air > 0.8 m from the patient and remain airborne for more than 30 min (Hanak & Chatwin, 2010), thus a potential exposure threat to the health care workers (HCW). It must rather be provided in isolation rooms with negative pressures and HCW providing care should don quality PPE (grade 3 personal protective equipment).

The expert consensus guidelines recommend replacing nebulization with MDIs in COVID-19 disease; however, there are no dogmatic guidelines or protocols in this context (Abrams & Szefler, 2020). As far as pathophysiology is concerned, COPD is an obstructive airway pathology characterized by expiratory airflow limitation due to chronic inflammation of the large central airways, peripheral bronchioles, and destruction of lung parenchyma. On the contrary, in COVID-19, Mu X et al. observed it to be primarily a restrictive ventilatory defect along with impairment of diffusion capacity as reflected by the pulmonary function tests in 110 discharged survivors with COVID 19 (Mo et al., 2020). Therefore, COVID patients with COPD may present with mixed pattern (obstructive and restrictive) which may affect the performance of the aforementioned modes of bronchodilation.

We emphasize the need for assessing the risk-benefit ratio related to the safety of HCW with the use of MDI plus spacer versus the risk of clinical deterioration by avoiding nebulization in patients with COVID-19 disease with COPD. We also recommend the need for further research and evidence-based concrete guidelines in context to the favorable mode of inhaled bronchodilator in COVID-19 disease.

Availability of data and materials

Not applicable.

Abbreviations

MDI:

Metered dose inhaler

COVID:

Coronavirus disease

COPD:

Chronic obstructive pulmonary disease

FiO2:

Fraction of inspired oxygen

FEV1:

Forced expiratory volume in 1 s

DPI:

Dry powder inhaler

HCW:

Health care worker

References

  1. Abrams EM, Szefler SJ (2020) Managing asthma during coronavirus disease-2019: an example for other chronic conditions in children and adolescents. J Pediatr 222:221–226

    CAS  Article  Google Scholar 

  2. Simonds AK, Hanak A, Chatwin M (2010) Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess 14(46):131–172

    CAS  Article  Google Scholar 

  3. Mo X, Jian W, Su Z, Chen M, Peng H, Peng P et al (2020) Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 55(6):2001217

    CAS  Article  Google Scholar 

  4. Turner MO, Patel A, Ginsburg S, FitzGerald JM (1997) Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med 157(15):1736–1744

    CAS  Article  Google Scholar 

  5. van Geffen WH, Douma WR, Slebos DJ, Kerstjens HA (2016) Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev 8:CD011826

    Google Scholar 

Download references

Acknowledgements

Nursing officers Mr. Mahendra Pal Singh Jatol and Mr. Mukesh Choudhary (All India Institute of Medical Sciences, Nagpur, India)

Funding

None.

Author information

Affiliations

Authors

Contributions

GTC contributed to the conception and drafting of the manuscript. PGG contributed to the drafting and critical review. SST contributed to the drafting of the manuscript. All authors have read and approved the manuscript.

Corresponding author

Correspondence to Prakash G. Gondode.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

A written informed consent for publication was obtained from both the patients.

Competing interests

The authors declare that they have no competing interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chilkoti, G.T., Gondode, P.G. & Tiwari, S.S. MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better?. Ain-Shams J Anesthesiol 13, 24 (2021). https://doi.org/10.1186/s42077-021-00148-4

Download citation

\